{"entity":{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","aka":[],"tldr":"The Indian company whose trispecific antibody ISB 2001 for multiple myeloma was licensed to AbbVie in 2025 for 700 million dollars upfront, the largest deal for an Indian-discovered cancer drug.","summary":"Glenmark was founded on 18 November 1977 by Gracias Saldanha in Mumbai. In January 2024 it consolidated oncology discovery into Ichnos Glenmark Innovation (IGI), a venture with its subsidiary Ichnos Sciences, with three molecules in the clinic at launch. In July 2025 IGI licensed ISB 2001, a BCMA x CD38 x CD3 trispecific T-cell engager in phase 1 for relapsed or refractory multiple myeloma, to AbbVie for 700 million dollars upfront and up to 1.225 billion dollars in milestones plus royalties; AbbVie took North America, Europe, Japan and Greater China and Glenmark kept India and emerging markets. In 2025 Glenmark also in-licensed the HER2 ADC trastuzumab rezetecan from Hengrui (a deal valued at up to 1.1 billion dollars) and the EGFR inhibitor aumolertinib from Hansoh for several regions.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.glenmarkpharma.com"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["immunotherapy","adcs"],"technologies":["t-cell-engager","bispecific-antibody","adc"],"targets":["bcma","cd38","her2"],"drugs":["isb-2001","trastuzumab-rezetecan"],"companies":["abbvie","hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"pharma","website":"https://www.glenmarkpharma.com","ticker":"GLENMARK.NS","founded":1977,"investors":[],"funding":[]},"route":"/companies/glenmark/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"isb-2001","kind":"drug","name":"ISB 2001","route":"/drugs/isb-2001/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"bottleneck":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}]}}